专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL276203D0 Compositions and methods of treating cancer 未知
公开(公告)号：IL276203D0
公开(公告)日：2020-09-30
申请号：IL27620320
申请日：2020-07-21
申请人： SQUIBB BRISTOL MYERS CO , ZHAO QIHONG , FARGNOLI JOSEPH , GURURAJAN MURALI , WEE SUSAN
发明人： ZHAO QIHONG , FARGNOLI JOSEPH , GURURAJAN MURALI , WEE SUSAN
IPC分类号： A61K9/00 , A61K31/53 , A61K39/00 , A61K39/395 , A61K45/06 , A61P35/00 , A61P35/04 , C07K16/28
摘要： The invention is directed to methods of treating cancer in subjects with a combination comprising a CCR2/5 dual antagonist, such as N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide; a monoclonal antibody, such as nivolumab; and/or chemotherapy.

2. 发明申请

WO2006124689A2 COMBINATION THERAPY 审中-公开
标题翻译：组合治疗
公开(公告)号：WO2006124689A2
公开(公告)日：2006-11-23
申请号：PCT/US2006018579
申请日：2006-05-12
申请人： SQUIBB BRISTOL MYERS CO , FARGNOLI JOSEPH
发明人： FARGNOLI JOSEPH
IPC分类号： A61K31/53 , A61K39/395 , A61K45/06 , A61P35/00 , C07K16/00
CPC分类号： A61K45/06 , A61K31/53 , A61K39/39558 , A61K2039/505 , C07K16/2863 , A61K2300/00
摘要： This invention relates to a therapeutic combination of anti-cancer compounds which comprises a) a VEGFR-2 inhibitor, and b) a substance that binds to the epidermal growth factor receptor (EGFR) and blocks the ability of epidermal growth factor (EGF) to initiate receptor activities which results in tumor growth inhibition, and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use.
摘要翻译：本发明涉及抗癌化合物的治疗组合，其包括a）VEGFR-2抑制剂，和b）与表皮生长因子受体（EGFR）结合并阻断表皮生长因子（EGF）的能力的物质启动导致肿瘤生长抑制的受体活性，以及任选的至少一种用于同时，分开或顺序使用的药学上可接受的载体。

3. 发明申请

WO2008127526A2 BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 MODULATORS 审中-公开
标题翻译：生物标志物和确定血管内皮生长因子受体2调节因子灵敏度的方法
公开(公告)号：WO2008127526A2
公开(公告)日：2008-10-23
申请号：PCT/US2008003258
申请日：2008-03-12
申请人： SQUIBB BRISTOL MYERS CO , WU SHUJIAN , AYERS MARK DAVID , HAN XIA , YOGANATHAN SUGANTHY , FARGNOLI JOSEPH
发明人： WU SHUJIAN , AYERS MARK DAVID , HAN XIA , YOGANATHAN SUGANTHY , FARGNOLI JOSEPH
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118
摘要： VEGFR-2 biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an VEGFR-2 modulator, wherein the method comprises (a) exposing the mammal to the VEGFR-2 modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the VEGFR-2 modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a VEGFR-2 modulator indicates that the mammal has responded therapeutically to the method of treating cancer.
摘要翻译：可用于鉴定和监测将对治疗癌症的治疗方法进行治疗的哺乳动物的方法中的VEGFR-2生物标志物，其包括施用VEGFR-2调节剂，其中所述方法包括（a）将哺乳动物暴露于VEGFR-2调节剂和（ b）在哺乳动物中测量至少一种生物标志物的水平，其中在（b）中测量的至少一种生物标志物水平的差异与尚未暴露于VEGFR的哺乳动物中的生物标志物的水平相比较 -2调节剂表明哺乳动物将对治疗癌症的方法进行治疗反应;（c）其中暴露于VEGFR-2调节剂后哺乳动物中生物标志物的水平表明哺乳动物对治疗癌症的方法有治疗反应。

4. 发明申请

WO2008127526A3 BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 MODULATORS 审中-公开
公开(公告)号：WO2008127526A3
公开(公告)日：2008-12-31
申请号：PCT/US2008003258
申请日：2008-03-12
申请人： SQUIBB BRISTOL MYERS CO , WU SHUJIAN , AYERS MARK DAVID , HAN XIA , YOGANATHAN SUGANTHY , FARGNOLI JOSEPH
发明人： WU SHUJIAN , AYERS MARK DAVID , HAN XIA , YOGANATHAN SUGANTHY , FARGNOLI JOSEPH
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118
摘要： VEGFR-2 biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an VEGFR-2 modulator, wherein the method comprises (a) exposing the mammal to the VEGFR-2 modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the VEGFR-2 modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a VEGFR-2 modulator indicates that the mammal has responded therapeutically to the method of treating cancer.

5. 发明申请

WO02067928A2 METRONOMIC DOSING OF TAXANES 审中-公开
标题翻译：泰铢计量
公开(公告)号：WO02067928A2
公开(公告)日：2002-09-06
申请号：PCT/US0205971
申请日：2002-02-26
申请人： SQUIBB BRISTOL MYERS CO , FARGNOLI JOSEPH , ROSE WILLIAM C , TRAIL PAMELA
发明人： FARGNOLI JOSEPH , ROSE WILLIAM C , TRAIL PAMELA
IPC分类号： C07D305/14 , A61K31/337 , A61K45/06 , A61P35/00
CPC分类号： A61K45/06 , A61K31/337 , A61K2300/00
摘要： A metronomic dosing regime for taxanes is provided which inhibits tumor growth in animals.
摘要翻译：提供紫杉烷的节律剂量给药方案，其抑制动物中的肿瘤生长。

6. 发明专利

ES2211374T3 DOSIFICACION METRONOMICA DE TAXANOS PARA INHIBIR EL CRECIMIENTO TUMORAL. 未知
公开(公告)号：ES2211374T3
公开(公告)日：2007-03-01
申请号：ES02723255
申请日：2002-02-26
申请人： SQUIBB BRISTOL MYERS CO
发明人： FARGNOLI JOSEPH , ROSE WILLIAM C , TRAIL PAMELA
IPC分类号： A61K31/337 , C07D305/14 , A61K45/06 , A61P35/00
摘要： Uso de un taxano para la fabricación de un medicamento para inhibir el crecimiento de un tumor y producir efectos secundarios menos tóxicos en comparación con la administración de la dosis máxima tolerada de taxano, en el que el taxano es administrado repetidamente en una dosis inferior a una dosis máxima tolerada establecida para el taxano.

7. 发明专利

UY27185A1 DOSIFICACIÓN METRONÓMICA DE TAXANOS 未知
公开(公告)号：UY27185A1
公开(公告)日：2002-09-30
申请号：UY27185
申请日：2002-02-25
申请人： SQUIBB BRISTOL MYERS CO
发明人： ROSE WILLIAM C , FARGNOLI JOSEPH
IPC分类号： C07D305/14 , A61K31/337 , A61K45/06 , A61P35/00
摘要： Se proporciona un régimen de dosificación metronómica para taxanos, el cual inhibe el desarrollo tumoral en animales.

8. 发明专利

PT646646E 未知
公开(公告)号：PT646646E
公开(公告)日：2000-07-31
申请号：PT94115482
申请日：1994-09-30
申请人： SQUIBB BRISTOL MYERS CO
发明人： SPANA CARL , FARGNOLI JOSEPH , BOLEN JOSEPH B
IPC分类号： A61K38/00 , C07K14/705 , C12N5/00 , C12N5/10 , C12N15/09 , C12N9/12 , C12N15/866 , C12P21/02 , C12R1/91 , C12N15/86 , C12N15/62
摘要： An expression system for producing and isolating large quantities of protein. This system employs an expression vector, comprising (a) a coding region for a glutathione-binding polypeptide (glutathione-s-transferase preferred), operatively connected to a promoter, (b) a second coding region in-frame with the first coding region, and (c) at least one restriction site between the first and second coding regions wherein a fusion protein of the first and second coding regions will result from expression of the vector. This vector is used in a host cell, which in turn is used in a process for isolating and purifying a protein. This process comprises (a) treating the host cell under conditions allowing expression of the vector, whereby a fusion protein of the first and second coding regions will be expressed; (b) exposing proteins from the host cell to glutathione resin, whereby the fusion protein will adhere to the resin; and (c) cleaving the expression product of the second coding region from the resin. Also described is a process for expressing a nucleic acid sequence, which comprises (a) inserting the nucleic acid sequence into a baculovirus expression vector in-frame with the first coding region; (b) placing the vector into a host cell; (c) treating the host cell under conditions allowing expression of the vector, resulting in expression of a fusion protein of the first coding region and the sequence inserted in step (a); (d) exposing proteins from the host cell to glutathione resin, whereby the fusion protein will adhere to the resin; and (e) treating the adhered fusion protein with a protease to release the expression product of the nucleic acid sequence from the resin. A baculovirus/Spodoptera frugiperda expression system is preferred.

9. 发明专利

AU2019209435A1 Compositions and methods of treating cancer 未知
公开(公告)号：AU2019209435A1
公开(公告)日：2020-09-17
申请号：AU2019209435
申请日：2019-01-22
申请人： SQUIBB BRISTOL MYERS CO
发明人： ZHAO QIHONG , FARGNOLI JOSEPH , GURURAJAN MURALI , WEE SUSAN
IPC分类号： A61K31/53 , A61K39/395 , A61P35/00
摘要： The invention is directed to methods of treating cancer in subjects with a combination comprising a CCR2/5 dual antagonist, such as N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide; a monoclonal antibody, such as nivolumab; and/or chemotherapy.

10. 发明专利

BRPI0610806A2 未知
公开(公告)号：BRPI0610806A2
公开(公告)日：2010-07-27
申请号：BRPI0610806
申请日：2006-05-12
申请人： SQUIBB BRISTOL MYERS CO
发明人： FARGNOLI JOSEPH
IPC分类号： A61K31/53 , A61K39/395 , A61K45/06 , A61P35/00 , C07K16/00
摘要： This invention relates to a therapeutic combination of anti-cancer compounds which comprises a) a VEGFR-2 inhibitor, and b) a substance that binds to the epidermal growth factor receptor (EGFR) and blocks the ability of epidermal growth factor (EGF) to initiate receptor activities which results in tumor growth inhibition, and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式